Literature DB >> 9713135

Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis.

I M de Medeiros1, A Castelo, R Salomão.   

Abstract

Experimental murine L. major infection is characterized by the expansion of distinct CD4+ T cell subsets. The Th1 response is related to production of IFN-gamma and resolution of infection, whereas Th-2 response with production of IL-4 and IL-10 and dissemination of infection. The objective of this study was to measure the circulating levels of IFN-gamma, IL-10 and TNF-alpha in patients with visceral leishmaniasis (VL) before, during and at the end of therapy and to examine the association between cytokine levels and activity of VL. Fifteen patients with VL were evaluated. The cytokine determinations were done by using the enzyme-linked immunoassay (ELISA) before, during and at the end of therapy. At baseline, we detected circulating levels of IFN-gamma in 13 of 15 patients (median = 60 pg/ml); IL-10 in 14 of 15 patients (median = 141.4 pg/ml); and TNF-alpha in 13 of 14 patients (median = 38.9 pg/ml). As patients improved, following antimonial therapy, circulating levels of IL-10 showed an exponential decay (y = 82.34 e-0, 10367x, r = -0.659; p < 0.001). IFN-gamma was no longer detected after 7/14 days of therapy. On the other hand, circulating levels of TNF-alpha had a less pronounced decay with time on therapy, remaining detectable in most patients during the first seven days of therapy (y = 36.99-0.933x, r = -0.31; p = 0.05). Part of the expression of a successful response to therapy may, therefore, include reduction in secretion of inflammatory as well as suppressive cytokines. Since IL-10 and IFN-gamma are both detected prior to therapy, the recognized cellular immune depression seen in these patients may be due to biological predominance of IL-10 (type 2 cytokine), rather than lack of IFN-gamma (type 1 cytokine) production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713135     DOI: 10.1590/s0036-46651998000100007

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  17 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Is the IL-10 -819 polymorphism associated with visceral leishmaniasis?

Authors:  Mehrdad Hajilooi; Kosro Sardarian; Maryam Dadmanesh; Mohamad Matini; Pegah Lotfi; Ahad Bazmani; Mohammad Amin Tabatabaiefar; Mohammad Kazemi Arababadi; Mohammad Momeni
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

3.  Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection.

Authors:  V Peruhype-Magalhães; O A Martins-Filho; A Prata; L De A Silva; A Rabello; A Teixeira-Carvalho; R M Figueiredo; S F Guimarães-Carvalho; T C A Ferrari; J Van Weyenbergh; R Correa-Oliveira
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

4.  Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.

Authors:  Henry W Murray; Christina M Lu; Smita Mauze; Sherry Freeman; Andre L Moreira; Gilla Kaplan; Robert L Coffman
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

5.  TGF-beta and mesenchymal hepatic involvement after visceral leishmaniasis.

Authors:  Maria Irma Seixas Duarte; Heitor Franco de Andrade; Cleusa Fumica Hirata Takamura; Antonio Sesso; Felipe Francisco Tuon
Journal:  Parasitol Res       Date:  2008-12-05       Impact factor: 2.289

6.  Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis.

Authors:  Sandeep Verma; Rajesh Kumar; Gajendra Kumar Katara; Laishram Chandreshwor Singh; Narender Singh Negi; V Ramesh; Poonam Salotra
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

7.  Leishmania donovani Secretory Mevalonate Kinase Regulates Host Immune Response and Facilitates Phagocytosis.

Authors:  Tanvir Bamra; Taj Shafi; Sushmita Das; Manjay Kumar; Manas Ranjan Dikhit; Ajay Kumar; Ashish Kumar; Kumar Abhishek; Krishna Pandey; Abhik Sen; Pradeep Das
Journal:  Front Cell Infect Microbiol       Date:  2021-04-26       Impact factor: 5.293

8.  Restoration of IFNγR subunit assembly, IFNγ signaling and parasite clearance in Leishmania donovani infected macrophages: role of membrane cholesterol.

Authors:  Subha Sen; Koushik Roy; Sandip Mukherjee; Rupkatha Mukhopadhyay; Syamal Roy
Journal:  PLoS Pathog       Date:  2011-09-08       Impact factor: 6.823

9.  Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis.

Authors:  Arlene Caldas; Cecília Favali; Dorlene Aquino; Vera Vinhas; Johan van Weyenbergh; Cláudia Brodskyn; Jackson Costa; Manoel Barral-Netto; Aldina Barral
Journal:  BMC Infect Dis       Date:  2005-12-19       Impact factor: 3.090

Review 10.  Pleiotropic Effect of Hormone Insulin-Like Growth Factor-I in Immune Response and Pathogenesis in Leishmaniases.

Authors:  Luiza C Reis; Eduardo Milton Ramos-Sanchez; Fernanda N Araujo; Ariane F Leal; Christiane Y Ozaki; Orlando R Sevillano; Bernardina A Uscata; Hiro Goto
Journal:  J Immunol Res       Date:  2021-05-04       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.